Fitch revises outlook on Jubilant Pharma to negative; affirms at 'BB'
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
The brand has added a range of exciting new products especially formulated for oily skin.
According to Fortune Business Insights, the launch of new PCR-based detection techniques will lead to a surge in demand for PCR instruments in the coming years
The partnership will help digitize and automate existing tasks traditionally managed on paper, significantly reducing costs and lead times while increasing compliance
With ValGenesis VLMS, change control driven validation activities are reduced from weeks to mere hours, and the company gains faster access to detailed metrics that help reduce costs and cycle time
Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines
The newly enhanced drug development platform will help empower innovators with the fastest development timelines
Dr. Raman has succeeded Victoria Richon
Evonik invests in start-up to improve patient recovery after open-chest surgery
Agilent will integrate the technology into its lab informatics platforms, enabling customers to automate GC/MS data analysis
Subscribe To Our Newsletter & Stay Updated